CV Outcomes and Adherence With GLP-1 RAs

This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Diabetes and CV Disease

EXSCEL CVOT Exenatide Once-Weekly

EXSCEL Once-Weekly Exenatide Results

Post-Hoc Analysis of EXSCEL

SUSTAIN 6 Once-Weekly Semaglutide Results

LEADER Once-Daily Liraglutide

Clinical Application of Results From LEADER

Clinical Application of Results From EXSCEL

ELIXA Once-Daily Lixisenatide

HARMONY Once-Weekly Albiglutide

ITCA-650 Implantable Exenatide

Adherence and Persistence

Manage Patient Expectations

Impact of Delivery Device on Patient Acceptance and Adherence

Consider Patient Preferences

2018 ADA/EASD Consensus Report GLP-1 Receptor Agonists With Proven CV Benefit

REWIND Once-Weekly Dulaglutide

Majority of People With T2D Have CV Disease

Primary Prevention

GLP-1 RAs and SGLT2 Inhibitors Reduce CV Outcomes

Concluding Remarks

Abbreviations